403 related articles for article (PubMed ID: 9168440)
1. Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.
Gagro A; Dasić G; Sabioncello A; Rabatić S; Reckzeh B; Havemann K; Kardum I; Jacksić B; Vitale B
Leuk Lymphoma; 1997 Apr; 25(3-4):301-11. PubMed ID: 9168440
[TBL] [Abstract][Full Text] [Related]
2. Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia.
Lopez-Matas M; Rodriguez-Justo M; Morilla R; Catovsky D; Matutes E
Haematologica; 2000 Nov; 85(11):1140-5. PubMed ID: 11064465
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
[TBL] [Abstract][Full Text] [Related]
4. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc(epsilon)IIR) proteins in human malignant B cells.
Shubinsky G; Schlesinger M; Polliack A; Rabinowitz R
Leuk Lymphoma; 1997 May; 25(5-6):521-30. PubMed ID: 9250823
[TBL] [Abstract][Full Text] [Related]
5. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.
Nichols EM; Jones R; Watson R; Pepper CJ; Fegan C; Marchbank KJ
Oncotarget; 2015 Oct; 6(32):32669-80. PubMed ID: 26452134
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia.
Reinisch W; Willheim M; Hilgarth M; Gasché C; Mader R; Szepfalusi S; Steger G; Berger R; Lechner K; Boltz-Nitulescu G
J Clin Oncol; 1994 Oct; 12(10):2146-52. PubMed ID: 7931486
[TBL] [Abstract][Full Text] [Related]
7. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
8. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
9. TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia.
Szymańska A; Bojarska-Junak A; Drobiecki A; Tomczak W; Roliński J; Hus M; Hus I
Arch Immunol Ther Exp (Warsz); 2019 Feb; 67(1):55-65. PubMed ID: 30196472
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia.
Geisler CH; Larsen JK; Hansen NE; Hansen MM; Christensen BE; Lund B; Nielsen H; Plesner T; Thorling K; Andersen E
Blood; 1991 Oct; 78(7):1795-802. PubMed ID: 1717071
[TBL] [Abstract][Full Text] [Related]
11. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
[TBL] [Abstract][Full Text] [Related]
12. Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias.
Molica S; Mannella A; Crispino G; Dattilo A; Levato D
Haematologica; 1997; 82(5):555-9. PubMed ID: 9407720
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD23 antigen and its regulation by IL-4 in chronic lymphocytic leukemia.
Sarfati M; Fournier S; Christoffersen M; Biron G
Leuk Res; 1990; 14(1):47-55. PubMed ID: 2137545
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
15. CD40 ligand, Bcl-2 and apoptosis in B-chronic lymphocytic leukemia.
Hussein OA; Omran AA; Elnaggar AM; Fathy A
Egypt J Immunol; 2009; 16(2):27-36. PubMed ID: 22059351
[TBL] [Abstract][Full Text] [Related]
16. Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.
Low HZ; Hilbrans D; Schmidt-Wolf IG; Illges H
Int J Hematol; 2012 Sep; 96(3):350-6. PubMed ID: 22899340
[TBL] [Abstract][Full Text] [Related]
17. CD23 and chronic lymphocytic leukemia.
Sarfati M
Blood Cells; 1993; 19(3):591-6; discussion 597-9. PubMed ID: 8018941
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia.
Cioca DP; Kitano K
Leukemia; 2002 Mar; 16(3):335-43. PubMed ID: 11896536
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.
Almasri NM; Duque RE; Iturraspe J; Everett E; Braylan RC
Am J Hematol; 1992 Aug; 40(4):259-63. PubMed ID: 1380203
[TBL] [Abstract][Full Text] [Related]
20. Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia.
Romano C; Sellitto A; Chiurazzi F; Simeone L; De Fanis U; Raia M; Del Vecchio L; Lucivero G
Int J Hematol; 2015 Jan; 101(1):67-74. PubMed ID: 25432435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
